Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Sep;74(5):753–758. doi: 10.1038/bjc.1996.432

Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients.

H Robson 1, E Anderson 1, R D James 1, P F Schofield 1
PMCID: PMC2074698  PMID: 8795578

Abstract

Members of the transforming growth factor beta (TGF-beta family, in particular TGF-beta 1, are some of the most potent inhibitory growth factors in a variety of cell types. Resistance to TGF-beta 1-induced growth inhibition is frequently observed in colorectal carcinomas and is associated with tumour progression. Perturbations of TGF-beta 1 expression and function, therefore, may contribute to the loss of some constraints on tumour cell growth. In this study we have examined the expression of TGF-beta 1 and its precursor latency-associated peptide (LAP)-TGF-beta in human colorectal tumours using immunohistochemical techniques. In 86% of the tumours the LAP-TGF-beta complex was present in both the stromal and epithelial cells, whereas the mature TGF-beta 1 peptide was expressed in the glandular epithelium of 58.3% of these tumours. Intense staining for TGF-beta 1 was positively associated with advanced Dukes' stage. Furthermore, there was a significant correlation between the presence of TGF-beta 1 in the tumours and a shorter post-operative survival. This was most significant in a subgroup of patients who had received only a palliative operation. These results suggest that TGF-beta 1 expression may be useful as an independent prognostic indicator for a subgroup of patients who have a particularly poor prognosis.

Full text

PDF
753

Images in this article

755Figure 1
on p.755
755Figure 2
on p.755

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arrick B. A., Lopez A. R., Elfman F., Ebner R., Damsky C. H., Derynck R. Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor beta 1. J Cell Biol. 1992 Aug;118(3):715–726. doi: 10.1083/jcb.118.3.715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arteaga C. L., Carty-Dugger T., Moses H. L., Hurd S. D., Pietenpol J. A. Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ. 1993 Mar;4(3):193–201. [PubMed] [Google Scholar]
  3. Avery A., Paraskeva C., Hall P., Flanders K. C., Sporn M., Moorghen M. TGF-beta expression in the human colon: differential immunostaining along crypt epithelium. Br J Cancer. 1993 Jul;68(1):137–139. doi: 10.1038/bjc.1993.301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baigrie R. J., Berry A. R. Management of advanced rectal cancer. Br J Surg. 1994 Mar;81(3):343–352. doi: 10.1002/bjs.1800810307. [DOI] [PubMed] [Google Scholar]
  5. Barcellos-Hoff M. H., Derynck R., Tsang M. L., Weatherbee J. A. Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest. 1994 Feb;93(2):892–899. doi: 10.1172/JCI117045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chakrabarty S., Fan D., Varani J. Modulation of differentiation and proliferation in human colon carcinoma cells by transforming growth factor beta 1 and beta 2. Int J Cancer. 1990 Sep 15;46(3):493–499. doi: 10.1002/ijc.2910460328. [DOI] [PubMed] [Google Scholar]
  7. Chen R. H., Ebner R., Derynck R. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities. Science. 1993 May 28;260(5112):1335–1338. doi: 10.1126/science.8388126. [DOI] [PubMed] [Google Scholar]
  8. Coffey R. J., Jr, Shipley G. D., Moses H. L. Production of transforming growth factors by human colon cancer lines. Cancer Res. 1986 Mar;46(3):1164–1169. [PubMed] [Google Scholar]
  9. Friess H., Yamanaka Y., Büchler M., Ebert M., Beger H. G., Gold L. I., Korc M. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology. 1993 Dec;105(6):1846–1856. doi: 10.1016/0016-5085(93)91084-u. [DOI] [PubMed] [Google Scholar]
  10. Geiser A. G., Burmester J. K., Webbink R., Roberts A. B., Sporn M. B. Inhibition of growth by transforming growth factor-beta following fusion of two nonresponsive human carcinoma cell lines. Implication of the type II receptor in growth inhibitory responses. J Biol Chem. 1992 Feb 5;267(4):2588–2593. [PubMed] [Google Scholar]
  11. Gorsch S. M., Memoli V. A., Stukel T. A., Gold L. I., Arrick B. A. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res. 1992 Dec 15;52(24):6949–6952. [PubMed] [Google Scholar]
  12. Harpel J. G., Metz C. N., Kojima S., Rifkin D. B. Control of transforming growth factor-beta activity: latency vs. activation. Prog Growth Factor Res. 1992;4(4):321–335. doi: 10.1016/0955-2235(92)90014-9. [DOI] [PubMed] [Google Scholar]
  13. Hirayama D., Fujimori T., Satonaka K., Nakamura T., Kitazawa S., Horio M., Maeda S., Nagasako K. Immunohistochemical study of epidermal growth factor and transforming growth factor-beta in the penetrating type of early gastric cancer. Hum Pathol. 1992 Jun;23(6):681–685. doi: 10.1016/0046-8177(92)90325-w. [DOI] [PubMed] [Google Scholar]
  14. Jasani B., Wyllie F. S., Wright P. A., Lemoine N. R., Williams E. D., Wynford-Thomas D. Immunocytochemically detectable TGF-beta associated with malignancy in thyroid epithelial neoplasia. Growth Factors. 1990;2(2-3):149–155. doi: 10.3109/08977199009071501. [DOI] [PubMed] [Google Scholar]
  15. Jass J. R. Prognostic variables in large bowel cancer. J Clin Pathol. 1989 Sep;42(9):1006–1007. doi: 10.1136/jcp.42.9.1006-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Khan S., Raza A., Petrelli N., Mittleman A. In vivo determinations of labelling index of metastatic colorectal carcinoma and normal colonic mucosa using intravenous infusions of bromodeoxyuridine. J Surg Oncol. 1988 Oct;39(2):114–118. doi: 10.1002/jso.2930390209. [DOI] [PubMed] [Google Scholar]
  17. La Rocca R. V., Park J. G., Danesi R., Del Tacca M., Steinberg S. M., Gazdar A. F. Pattern of growth factor, proto-oncogene and carcinoembryonic antigen gene expression in human colorectal carcinoma cell lines. Oncology. 1992;49(3):209–214. doi: 10.1159/000227040. [DOI] [PubMed] [Google Scholar]
  18. Manning A. M., Williams A. C., Game S. M., Paraskeva C. Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor beta (TGF-beta): conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-beta. Oncogene. 1991 Aug;6(8):1471–1476. [PubMed] [Google Scholar]
  19. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J., Fan R. S., Zborowska E., Kinzler K. W., Vogelstein B. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995 Jun 2;268(5215):1336–1338. doi: 10.1126/science.7761852. [DOI] [PubMed] [Google Scholar]
  20. Massagué J., Cheifetz S., Laiho M., Ralph D. A., Weis F. M., Zentella A. Transforming growth factor-beta. Cancer Surv. 1992;12:81–103. [PubMed] [Google Scholar]
  21. McCartney-Francis N. L., Wahl S. M. Transforming growth factor beta: a matter of life and death. J Leukoc Biol. 1994 Mar;55(3):401–409. doi: 10.1002/jlb.55.3.401. [DOI] [PubMed] [Google Scholar]
  22. Miyazono K., Ten Dijke P., Ichijo H., Heldin C. H. Receptors for transforming growth factor-beta. Adv Immunol. 1994;55:181–220. [PubMed] [Google Scholar]
  23. Mulder K. M., Levine A. E., Hernandez X., McKnight M. K., Brattain D. E., Brattain M. G. Modulation of c-myc by transforming growth factor-beta in human colon carcinoma cells. Biochem Biophys Res Commun. 1988 Jan 29;150(2):711–716. doi: 10.1016/0006-291x(88)90449-4. [DOI] [PubMed] [Google Scholar]
  24. Murthy U., Anzano M. A., Greig R. G. Expression of TGF-alpha/EGF and TGF-beta receptors in human colon carcinoma cell lines. Int J Cancer. 1989 Jul 15;44(1):110–115. doi: 10.1002/ijc.2910440120. [DOI] [PubMed] [Google Scholar]
  25. O'Connell M. J., Gunderson L. L. Adjuvant therapy for adenocarcinoma of the rectum. World J Surg. 1992 May-Jun;16(3):510–515. doi: 10.1007/BF02104456. [DOI] [PubMed] [Google Scholar]
  26. Odekon L. E., Blasi F., Rifkin D. B. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta. J Cell Physiol. 1994 Mar;158(3):398–407. doi: 10.1002/jcp.1041580303. [DOI] [PubMed] [Google Scholar]
  27. Rothenberger D. A. Relevant clinical information and tumor markers. Cancer. 1993 Jun 15;71(12 Suppl):4193–4197. doi: 10.1002/1097-0142(19930615)71:12+<4193::aid-cncr2820711806>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  28. Schmoll H. J. Colorectal carcinoma: current problems and future perspectives. Ann Oncol. 1994;5 (Suppl 3):115–121. doi: 10.1093/annonc/5.suppl_3.s115. [DOI] [PubMed] [Google Scholar]
  29. Schofield P. F., Walsh S., Tweedle D. E. Survival after treatment of carcinoma of the rectum. Br Med J (Clin Res Ed) 1986 Aug 23;293(6545):496–497. doi: 10.1136/bmj.293.6545.496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Steiner M. S., Barrack E. R. Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol. 1992 Jan;6(1):15–25. doi: 10.1210/mend.6.1.1738367. [DOI] [PubMed] [Google Scholar]
  31. Thompson T. C., Truong L. D., Timme T. L., Kadmon D., McCune B. K., Flanders K. C., Scardino P. T., Park S. H. Transforming growth factor beta 1 as a biomarker for prostate cancer. J Cell Biochem Suppl. 1992;16H:54–61. doi: 10.1002/jcb.240501212. [DOI] [PubMed] [Google Scholar]
  32. Wakefield L. M., Smith D. M., Broz S., Jackson M., Levinson A. D., Sporn M. B. Recombinant TGF-beta 1 is synthesized as a two-component latent complex that shares some structural features with the native platelet latent TGF-beta 1 complex. Growth Factors. 1989;1(3):203–218. doi: 10.3109/08977198908997997. [DOI] [PubMed] [Google Scholar]
  33. Walker R. A., Dearing S. J. Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer. 1992;28(2-3):641–644. doi: 10.1016/s0959-8049(05)80116-9. [DOI] [PubMed] [Google Scholar]
  34. Wolmark N., Rockette H., Fisher B., Wickerham D. L., Redmond C., Fisher E. R., Jones J., Mamounas E. P., Ore L., Petrelli N. J. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993 Oct;11(10):1879–1887. doi: 10.1200/JCO.1993.11.10.1879. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES